Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Maintains Its Momentum During Pandemic

Executive Summary

The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.

You may also be interested in...



BIO 2020 Notebook: McMurry-Heath On Restoring Hope, Greenwood On Defeating Climate Skeptics

News and views from day one of  BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change. 

BIO 2020 Notebook: McMurry-Heath On Restoring Hope, Greenwood On Defeating Climate Skeptics

News and views from day one of BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change. 

‘Friendly Breakup’: Sanofi And Regeneron Agree Equity Revamp

Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel